Moximed’s MISHA™ Knee System Achieves Superiority of Primary Endpoint in Pivotal Study
Implantable shock absorber demonstrates clinically meaningful pain relief and functional improvement in data presented at OSET
Excerpt from the Press Release:
FREMONT, Calif.–(BUSINESS WIRE)–Moximed, a medical device company on a mission to improve the standard of care for people suffering with chronic knee pain due to osteoarthritis (OA), today announced clinical results presented at the 12th Orthopaedic Summit (OSET) in Boston.
David R. Diduch, MD, the A.F. Voshell Professor of Sports Medicine, Department of Sports Medicine, University of Virginia, presented results from the pivotal Calypso Study of the MISHA™ Knee System, an implantable shock absorber (ISA) for the treatment of knee osteoarthritis. The Calypso Study demonstrated superiority of its primary endpoint and reported clinically significant reduction in pain scores and improvement in function scores for participants receiving the MISHA Knee System.
Designed to relieve pain, preserve function, and offer a treatment option that could potentially delay arthroplasty, the MISHA Knee System is an implantable shock absorber developed to unload on the knee with every walking step.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?